Browse by category

China's National Medical Products Administration (NMPA) has approved Innovent Biologics’ mazdutide, a first-in-class dual glucagon...

The first participant has been successfully dosed in a Phase 3 clinical trial (GLORY-OSA) of mazdutide, a dual glucagon (GCG) and...

The results from GLORY-1 - a Phase 3 clinical study of mazdutide - a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor...

Innovent Biologics’ Phase 3 clinical trial (DREAMS-1) of mazdutide a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor...

Innovent Biologics has announced the key results of the first Phase 3 clinical trial of mazdutide in Chinese adults with overweight or...

Innovent Biologics’ Phase 3 clinical trial (DREAMS-2) of mazdutide (IBI362) in Chinese subjects with type 2 diabetes (T2D) has met its...

The first participant has been successfully dosed in Innovent Biologics’ Phase 3 clinical trial (GLORY-2) of higher dose 9mg mazdutide, a...

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

Innovent Biologics has revealed its phase 2 clinical study of higher dose (9mg) mazdutide in Chinese adults with obesity achieved the...

Innovent Biologics has announced that the first participant has been successfully dosed in the higher-dose cohort of a phase 2 clinical...